Stock Analysts

Progressive’s (PGR) Premium Growth Impresses, Cat Loss a Woe

The Progressive Corporation PGR has successfully catered to the evolving demands and expectations of clients for years, thereby building a robust product and service portfolio over time. This in turn has helped the property and casualty (P&C) insurer become a one-stop insurance destination through the meeting of its customers’ requirements, mainly opting for a combination of home and auto. Progressive has maintained its industry-leading position in product, service and distribution innovation, particularly personal auto […]

Stock Analysts

Boston Scientific’s Resonate Devices Boost Cardiac Rhythm Arm

Boston Scientific BSX recently launched an advanced Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure Diagnostic. Notably, these devices are FDA approved for conditional use in a magnetic resonance imaging (MRI) environment and help physicians improve heart failure (HF) management through personalized care. The devices combine the company's SmartCRT Technology with EnduraLife Battery Technology. […]

Stock Analysts

Will Colgate’s Strategic Initiatives Help Counter Sales Woes?

Colgate-Palmolive Company CL continues to progress well with its savings programs along with a disciplined capital strategy and other initiatives. However, the company has a dismal sales trend. Savings Programs Bode Well Colgate remains committed to its savings programs as both Global Growth and Efficiency Program (or 2012 Restructuring Program) as well as Funding the Growth initiatives are delivering impressive results. […]

Stock Analysts

Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes

We issued an updated research report on Allergan plc AGN on Sep 26. Allergan boasts dominant growth franchises in several areas and is strengthening its product portfolio through strategic acquisitions. In 2017 so far, through the accretive acquisitions of LifeCell and ZELTIQ, Allergan has expanded its medical aesthetics business into regenerative medicine and body sculpting, respectively […]

Stock Analysts

Infosys (INFY) Rides High on Renew New Program, Hikes View

Infosys Limited INFY managed to impress investors with first-quarter fiscal 2018 results, wherein its earnings beat estimates by 4.3%. Infosys’ Renew New strategy, strategic partnerships, new offerings are proving conductive to the company’s impressive performance, consequently stoking growth. We believe that the earnings momentum is likely to continue as it has plenty ofroom to run. […]

Stock Analysts

Mellanox (MLNX) Drives on Growing Clientele, Collaborations

Mellanox Technologies Inc . MLNX is riding high on expanding customer base and portfolio strength driven by strategic partnerships. To date in 2017, the company’s products have been selected by cloud computing and semiconductor bigwigs like Hewlett Packard Enterprise HPE , Alibaba Group BABA and Advanced Micro Devices Inc AMD . […]

Stock Analysts

Should You Hold Eversource (ES) Stock in Your Portfolio Now?

Eversource Energy ES transmits and delivers electricity and natural gas to more than 3.7 million residential, commercial and industrial customers in Connecticut, New Hampshire and Massachusetts. Retaining this energy delivery company in your portfolio now is a good idea, given the following positive factors. Positive Growth Projections : The Zacks Consensus Estimate for earnings is $3.17 on revenues of $7.86 billion for 2017 […]

Stock Analysts

How Will Trump’s Proposed Tax Reform Impact Drug Companies?

During his presidential campaign, Donald Trump had stressed on tax reforms and promised that bringing down corporate tax would be his top priority as the President of the United States. Keeping his words, Trump proposed changes in tax rates for both individuals and corporates to stimulate economic growth as well as employment growth. […]